Market News

Ion Asset Management LTD Lowered Position in Camtek Limited (CAMT) by $1.44 Million as Stock Rose; Abbvie (ABBV) Shareholder American Asset Management Has Trimmed Its Holding by $306,680 as Valuation Rose

American Asset Management Inc decreased its stake in Abbvie Inc (ABBV) by 39.82% based on its latest 2017Q3 regulatory filing with the SEC. American Asset Management Inc sold 3,485 shares as the company’s stock rose 6.17% with the market. The institutional investor held 5,266 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $468,000, down from 8,751 at the end of the previous reported quarter. American Asset Management Inc who had been investing in Abbvie Inc for a number of months, seems to be less bullish one the $180.52B market cap company. The stock increased 1.09% or $1.22 during the last trading session, reaching $113.08. About 6.19M shares traded or 7.06% up from the average. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since February 15, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

Bart Baum decreased its stake in Camtek Limited (CAMT) by 52.22% based on its latest 2017Q3 regulatory filing with the SEC. Ion Asset Management Ltd sold 288,945 shares as the company’s stock rose 34.14% with the market. The hedge fund run by Bart Baum held 264,327 shares of the electronic components company at the end of 2017Q3, valued at $1.35M, down from 553,272 at the end of the previous reported quarter. Ion Asset Management Ltd who had been investing in Camtek Limited for a number of months, seems to be less bullish one the $233.27 million market cap company. The stock increased 1.72% or $0.11 during the last trading session, reaching $6.51. About 33,429 shares traded. Camtek Ltd. (NASDAQ:CAMT) has risen 166.84% since February 15, 2017 and is uptrending. It has outperformed by 150.14% the S&P500.

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 2 Sell and 9 Hold. Therefore 48% are positive. Abbvie Inc had 78 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was downgraded by JP Morgan to “Neutral” on Thursday, September 8. On Friday, September 15 the stock rating was maintained by Jefferies with “Buy”. Cowen & Co maintained it with “Buy” rating and $130.0 target in Friday, January 26 report. Barclays Capital downgraded the shares of ABBV in report on Tuesday, December 1 to “Equal-Weight” rating. The rating was downgraded by Leerink Swann to “Hold” on Monday, January 29. As per Friday, February 5, the company rating was initiated by William Blair. The firm has “Hold” rating given on Wednesday, June 7 by Credit Suisse. The rating was downgraded by UBS on Monday, September 25 to “Neutral”. The rating was upgraded by Leerink Swann on Monday, October 2 to “Outperform”. The firm has “Hold” rating given on Sunday, July 30 by BMO Capital Markets.

Since September 11, 2017, it had 0 buys, and 5 sales for $25.59 million activity. SALEKI-GERHARDT AZITA sold 8,300 shares worth $705,655. Michael Robert A. sold 6,699 shares worth $589,512. 18,300 shares were sold by Gosebruch Henry O, worth $1.66 million. The insider Schumacher Laura J sold $14.07 million.

Investors sentiment decreased to 0.85 in Q3 2017. Its down 0.15, from 1 in 2017Q2. It is negative, as 55 investors sold ABBV shares while 640 reduced holdings. 132 funds opened positions while 462 raised stakes. 1.06 billion shares or 1.89% more from 1.04 billion shares in 2017Q2 were reported. Guinness Atkinson Asset Mngmt holds 0.19% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 3,480 shares. American Commercial Bank accumulated 8,583 shares. Rmb Capital Limited Liability Company owns 58,715 shares. First Western Management has invested 0.53% of its portfolio in AbbVie Inc. (NYSE:ABBV). Armstrong Henry H Associate Inc invested in 0.4% or 24,841 shares. Nj State Employees Deferred Compensation Plan has 40,000 shares. Kemper Master Retirement reported 2.2% in AbbVie Inc. (NYSE:ABBV). First Hawaiian National Bank & Trust holds 10,397 shares. Lipe And Dalton accumulated 5,370 shares or 0.34% of the stock. Meiji Yasuda Life Insur Communication owns 0.7% invested in AbbVie Inc. (NYSE:ABBV) for 53,316 shares. Independent Investors invested in 2.01% or 54,500 shares. Foyston Gordon Payne holds 0.19% or 12,275 shares. Janney Mngmt Llc reported 7,754 shares. 18,149 were reported by Symphony Asset Ltd Liability Corporation. Fjarde Ap reported 0.64% of its portfolio in AbbVie Inc. (NYSE:ABBV).

Among 5 analysts covering Camtek Ltd (NASDAQ:CAMT), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Camtek Ltd had 15 analyst reports since July 27, 2015 according to SRatingsIntel. The company was maintained on Wednesday, February 7 by Needham. The rating was maintained by Chardan Capital Markets on Thursday, July 30 with “Buy”. B. Riley & Co maintained the shares of CAMT in report on Thursday, February 8 with “Buy” rating. The stock of Camtek Ltd. (NASDAQ:CAMT) has “Hold” rating given on Tuesday, June 27 by Needham. The stock has “Buy” rating by Needham on Friday, July 22. Zacks upgraded Camtek Ltd. (NASDAQ:CAMT) rating on Thursday, August 6. Zacks has “Hold” rating and $3 target. Needham maintained the stock with “Buy” rating in Friday, February 12 report. The stock of Camtek Ltd. (NASDAQ:CAMT) has “Hold” rating given on Monday, September 18 by Needham. On Tuesday, October 3 the stock rating was upgraded by Needham to “Buy”. Zacks upgraded Camtek Ltd. (NASDAQ:CAMT) on Friday, September 4 to “Buy” rating.

Leave a Reply

Your email address will not be published. Required fields are marked *